Biomolecule-functionalized nanoformulations for prostate cancer theranostics.
Biofunctionalization
Combinational therapy
Prostate cancer
Prostate-specific diagnosis
Journal
Journal of advanced research
ISSN: 2090-1224
Titre abrégé: J Adv Res
Pays: Egypt
ID NLM: 101546952
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
12
06
2022
revised:
21
10
2022
accepted:
03
11
2022
medline:
12
9
2023
pubmed:
12
11
2022
entrez:
11
11
2022
Statut:
ppublish
Résumé
Even with the advancement in the areas of cancer nanotechnology, prostate cancer still poses a major threat to men's health. Nanomaterials and nanomaterial-derived theranostic systems have been explored for diagnosis, imaging, and therapy for different types of cancer still, for prostate cancer they have not delivered at full potential because of the limitations like in vivo biocompatibility, immune responses, precise targetability, and therapeutic outcome associated with the nanostructured system. Functionalizing nanomaterials with different biomolecules and bioactive agents provides advantages like specificity towards cancerous tumors, improved circulation time, and modulation of the immune response leading to early diagnosis and targeted delivery of cargo at the site of action. In this review, we have emphasized the classification and comparison of various nanomaterials based on biofunctionalization strategy and source of biomolecules such that it can be used for possible translation in clinical settings and future developments. This review highlighted the opportunities for embedding highly specific biological targeting moieties (antibody, aptamer, oligonucleotides, biopolymer, peptides, etc.) on nanoparticles which can improve the detection of prostate cancer-associated biomarkers at a very low limit of detection, direct visualization of prostate tumors and lastly for its therapy. Lastly, special emphasis was given to biomimetic nanomaterials which include functionalization with extracellular vesicles, exosomes and viral particles and their application for prostate cancer early detection and drug delivery. The present review paves a new pathway for next-generation biofunctionalized nanomaterials for prostate cancer theranostic application and their possibility in clinical translation.
Sections du résumé
BACKGROUND
Even with the advancement in the areas of cancer nanotechnology, prostate cancer still poses a major threat to men's health. Nanomaterials and nanomaterial-derived theranostic systems have been explored for diagnosis, imaging, and therapy for different types of cancer still, for prostate cancer they have not delivered at full potential because of the limitations like in vivo biocompatibility, immune responses, precise targetability, and therapeutic outcome associated with the nanostructured system.
AIM OF REVIEW
Functionalizing nanomaterials with different biomolecules and bioactive agents provides advantages like specificity towards cancerous tumors, improved circulation time, and modulation of the immune response leading to early diagnosis and targeted delivery of cargo at the site of action.
KEY SCIENTIFIC CONCEPTS OF REVIEW
In this review, we have emphasized the classification and comparison of various nanomaterials based on biofunctionalization strategy and source of biomolecules such that it can be used for possible translation in clinical settings and future developments. This review highlighted the opportunities for embedding highly specific biological targeting moieties (antibody, aptamer, oligonucleotides, biopolymer, peptides, etc.) on nanoparticles which can improve the detection of prostate cancer-associated biomarkers at a very low limit of detection, direct visualization of prostate tumors and lastly for its therapy. Lastly, special emphasis was given to biomimetic nanomaterials which include functionalization with extracellular vesicles, exosomes and viral particles and their application for prostate cancer early detection and drug delivery. The present review paves a new pathway for next-generation biofunctionalized nanomaterials for prostate cancer theranostic application and their possibility in clinical translation.
Identifiants
pubmed: 36368516
pii: S2090-1232(22)00250-8
doi: 10.1016/j.jare.2022.11.001
pmc: PMC10491979
pii:
doi:
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
197-217Subventions
Organisme : NCI NIH HHS
ID : R01 CA206069
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA210192
Pays : United States
Organisme : NIGMS NIH HHS
ID : SC1 GM139727
Pays : United States
Informations de copyright
Copyright © 2023. Production and hosting by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Bioact Mater. 2021 Feb 02;6(8):2479-2490
pubmed: 33553829
Oncol Lett. 2019 Apr;17(4):4024-4033
pubmed: 30930999
Nat Nanotechnol. 2021 May;16(5):484-486
pubmed: 33846590
Anal Chem. 2018 Jul 17;90(14):8673-8679
pubmed: 29916251
Biomed Mater. 2008 Sep;3(3):034001
pubmed: 18689927
Nanomaterials (Basel). 2019 Jan 22;9(2):
pubmed: 30678236
Cancer Gene Ther. 2016 Oct;23(10):365-369
pubmed: 27740614
Int J Nanomedicine. 2014 Nov 21;9:5431-40
pubmed: 25473281
ACS Nano. 2019 Dec 24;13(12):13620-13626
pubmed: 31800203
Drug Deliv. 2021 Dec;28(1):1132-1140
pubmed: 34121558
Biosens Bioelectron. 2015 Dec 15;74:915-23
pubmed: 26257183
Front Mol Biosci. 2020 Nov 26;7:587012
pubmed: 33324678
Mikrochim Acta. 2020 Jan 10;187(2):116
pubmed: 31925569
Nanoscale. 2017 Nov 9;9(43):17020-17028
pubmed: 29082397
Nanoscale. 2021 Apr 30;13(16):7574-7582
pubmed: 33928988
Nanomedicine (Lond). 2016 Jan;11(1):9-30
pubmed: 26654241
ACS Appl Mater Interfaces. 2016 Nov 16;8(45):30722-30734
pubmed: 27786455
RSC Adv. 2018 Feb 9;8(12):6581-6589
pubmed: 35540394
Signal Transduct Target Ther. 2021 Jun 7;6(1):225
pubmed: 34099630
Front Pharmacol. 2019 Dec 18;10:1436
pubmed: 31920642
Anal Bioanal Chem. 2022 Feb;414(5):1921-1932
pubmed: 35001194
Adv Sci (Weinh). 2018 Dec 11;6(3):1801122
pubmed: 30775223
ACS Nano. 2014 May 27;8(5):4205-20
pubmed: 24730557
Int J Mol Sci. 2021 Feb 04;22(4):
pubmed: 33557050
ACS Nano. 2018 Apr 24;12(4):3714-3725
pubmed: 29641905
Nanomedicine. 2015 Jul;11(5):1277-83
pubmed: 25652893
Mikrochim Acta. 2019 Feb 2;186(3):152
pubmed: 30712215
Biomedicines. 2021 Feb 04;9(2):
pubmed: 33557143
J Clin Oncol. 2009 Nov 10;27(32):5431-8
pubmed: 19805692
J R Soc Interface. 2015 Jul 6;12(108):20150254
pubmed: 26109634
Chem Sci. 2019 Jul 18;10(35):8119-8128
pubmed: 31588336
JAMA. 2002 Apr 3;287(13):1662-70
pubmed: 11926890
Nanoscale. 2019 Nov 14;11(42):20058-20071
pubmed: 31612185
Biomed Pharmacother. 2020 Dec;132:110878
pubmed: 33113419
Eur Urol. 2011 Jan;59(1):81-7
pubmed: 20947244
J Nanobiotechnology. 2018 Sep 19;16(1):71
pubmed: 30231877
PLoS One. 2014 May 12;9(5):e97220
pubmed: 24819929
J Dig Dis. 2018 May;19(5):288-294
pubmed: 29687957
Clin Chem Lab Med. 2013 Apr;51(4):707-12
pubmed: 23518451
Biosens Bioelectron. 2022 Apr 15;202:114006
pubmed: 35091371
Bioconjug Chem. 2021 Jun 16;32(6):1146-1155
pubmed: 34011146
J Mater Chem B. 2014 Aug 14;2(30):4862-4867
pubmed: 32261777
Pharmaceutics. 2021 Apr 21;13(5):
pubmed: 33919150
Lancet. 2021 Sep 18;398(10305):1075-1090
pubmed: 34370973
ACS Nano. 2017 May 23;11(5):4926-4933
pubmed: 28441008
Adv Drug Deliv Rev. 2002 Sep 13;54(5):631-51
pubmed: 12204596
Adv Biosyst. 2017 May;1(5):e1700044
pubmed: 32646153
Langmuir. 2012 Jan 10;28(1):997-1004
pubmed: 22126088
Urology. 2007 Dec;70(6):1117-20
pubmed: 18158030
Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6315-20
pubmed: 16606824
Nanomedicine. 2020 Jul;27:102192
pubmed: 32229215
Chem Rev. 2008 Jul;108(7):2688-720
pubmed: 18558753
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Mikrochim Acta. 2018 Dec 18;186(1):33
pubmed: 30564911
Processes (Basel). 2020 May 13;8(5):580
pubmed: 33304843
Int J Pharm. 2016 Jul 25;509(1-2):16-27
pubmed: 27188645
Pathol Biol (Paris). 2015 Feb;63(1):32-4
pubmed: 25182691
Nat Commun. 2018 May 22;9(1):1944
pubmed: 29789598
Biosens Bioelectron. 2018 Nov 15;119:126-133
pubmed: 30121424
Molecules. 2021 Feb 28;26(5):
pubmed: 33670890
Cell Tissue Res. 2010 Jan;339(1):237-46
pubmed: 19513755
Arch Ital Urol Androl. 2006 Jun;78(2):39-43
pubmed: 16929600
N Engl J Med. 2004 May 27;350(22):2239-46
pubmed: 15163773
ACS Nano. 2014 Jun 24;8(6):5725-37
pubmed: 24848786
Anal Chim Acta. 2020 Apr 1;1104:53-59
pubmed: 32106957
ACS Appl Mater Interfaces. 2018 Nov 7;10(44):37829-37834
pubmed: 30360053
Biomed Pharmacother. 2020 Jul;127:110181
pubmed: 32416561
Int J Mol Sci. 2016 Mar 14;17(3):380
pubmed: 26985893
Int J Nanomedicine. 2017 Oct 27;12:7923-7936
pubmed: 29138559
Ann Transl Med. 2019 Mar;7(Suppl 1):S29
pubmed: 31032309
Clin Cancer Res. 2016 Jul 1;22(13):3157-63
pubmed: 26847057
Int J Nanomedicine. 2020 Dec 17;15:10305-10320
pubmed: 33376323
Langmuir. 2004 May 11;20(10):4226-35
pubmed: 15969421
Adv Mater. 2021 Oct;33(40):e2103999
pubmed: 34398465
Anal Biochem. 2013 Mar 1;434(1):123-7
pubmed: 23201390
Ann Fam Med. 2018 Mar;16(2):149-154
pubmed: 29531107
Bioconjug Chem. 2016 Sep 21;27(9):2111-23
pubmed: 27510221
Biomaterials. 2021 Aug;275:120946
pubmed: 34119884
Bioconjug Chem. 2020 Mar 18;31(3):448-461
pubmed: 31940187
ACS Appl Mater Interfaces. 2015 Oct 14;7(40):22578-86
pubmed: 26413999
Biomed Res Int. 2020 Apr 25;2020:9186583
pubmed: 32420382
Acta Biomater. 2022 Mar 15;141:408-417
pubmed: 35032718
J Biomed Mater Res B Appl Biomater. 2018 Jan;106(1):40-51
pubmed: 29218857
ACS Omega. 2017 May 31;2(5):1826-1835
pubmed: 30023645
Acta Biomater. 2020 Mar 15;105:1-14
pubmed: 32001369
Biosens Bioelectron. 2017 Mar 15;89(Pt 1):598-605
pubmed: 26868935
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Anal Biochem. 2017 Nov 1;536:51-58
pubmed: 28789963
Anal Chim Acta. 2018 Dec 7;1036:121-132
pubmed: 30253822
Appl Microbiol Biotechnol. 2011 Jun;90(5):1655-67
pubmed: 21523475
JAMA Oncol. 2018 Oct 1;4(10):1344-1351
pubmed: 29978216
Bioconjug Chem. 2016 Oct 19;27(10):2225-2238
pubmed: 27547843
J Control Release. 2011 Nov 7;155(3):435-41
pubmed: 21641946
Molecules. 2019 Dec 18;25(1):
pubmed: 31861277
N Engl J Med. 2004 Oct 7;351(15):1513-20
pubmed: 15470214
Drug Deliv. 2016;23(3):874-81
pubmed: 24892627
Cancer Cell. 2011 May 17;19(5):575-86
pubmed: 21575859
Macromol Biosci. 2017 May;17(5):
pubmed: 28128882
Drug Resist Updat. 2021 May;56:100762
pubmed: 33857756
J Drug Target. 2021 Sep;29(8):808-821
pubmed: 33645369
J Mater Chem B. 2014 Dec 28;2(48):8452-8465
pubmed: 32262204
Mater Today (Kidlington). 2020 Jul-Aug;37:112-125
pubmed: 33093794
Adv Drug Deliv Rev. 2020;156:214-235
pubmed: 32603813
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Bioeng Transl Med. 2016 May 27;1(1):30-46
pubmed: 29313005
Eur Urol. 2007 Nov;52(5):1309-22
pubmed: 17720304
Enzyme Microb Technol. 2018 May;112:43-51
pubmed: 29499779
Nanomaterials (Basel). 2021 Dec 23;12(1):
pubmed: 35009984
Oncotarget. 2017 Feb 7;8(6):9375-9387
pubmed: 28030843
Biosens Bioelectron. 2020 Feb 1;149:111830
pubmed: 31710919
Biomater Sci. 2021 Feb 21;9(4):1431-1448
pubmed: 33404026
Biomedicines. 2017 Aug 14;5(3):
pubmed: 28805744
Curr Top Med Chem. 2019;19(1):57-73
pubmed: 30686255
Cell Prolif. 2021 Nov;54(11):e13130
pubmed: 34599546
Int J Nanomedicine. 2015 Oct 19;10:6555-69
pubmed: 26527873
Sci Rep. 2021 Feb 2;11(1):2808
pubmed: 33531521
Int J Mol Sci. 2018 Nov 22;19(12):
pubmed: 30467297
Anal Biochem. 2018 Aug 15;555:1-8
pubmed: 29860096
ACS Sens. 2021 Apr 23;6(4):1418-1429
pubmed: 33755415
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
ACS Omega. 2019 May 22;4(5):8852-8861
pubmed: 31459973
Biosens Bioelectron. 2021 Jan 1;171:112729
pubmed: 33113387
Chem Soc Rev. 2016 May 3;45(9):2583-602
pubmed: 26954935
Cell Oncol (Dordr). 2016 Apr;39(2):97-106
pubmed: 26790878
Philos Trans A Math Phys Eng Sci. 2010 Mar 28;368(1915):1333-83
pubmed: 20156828
Nanomedicine. 2022 Feb;40:102477
pubmed: 34740868
Anal Chim Acta. 2014 Mar 25;818:54-60
pubmed: 24626403
Int J Cancer. 2014 Apr 1;134(7):1683-94
pubmed: 24105486
Biosens Bioelectron. 2018 Jun 1;107:178-183
pubmed: 29455028
Sci Rep. 2018 Jun 11;8(1):8867
pubmed: 29891921
Curr Pharm Des. 2020;26(42):5393-5413
pubmed: 32693761
Bioconjug Chem. 2021 Aug 18;32(8):1753-1762
pubmed: 34228917
Eur Urol. 2015 Dec;68(6):1033-44
pubmed: 25913390
Acta Physiol Scand. 1988 Nov;134(3):405-11
pubmed: 3227957
Bioact Mater. 2021 Aug 28;10:281-294
pubmed: 34901546
J Control Release. 2020 Apr 10;320:180-200
pubmed: 31978444
Mol Cancer Ther. 2016 Jan;15(1):106-113
pubmed: 26586724
J Mater Chem B. 2021 Jan 28;9(4):1151-1161
pubmed: 33434248
ACS Nano. 2017 Sep 26;11(9):9249-9258
pubmed: 28858475
Int J Nanomedicine. 2021 Jun 30;16:4391-4407
pubmed: 34234433
Talanta. 2016 Aug 15;156-157:218-224
pubmed: 27260456
Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17356-61
pubmed: 18978032
Talanta. 2020 Nov 1;219:121276
pubmed: 32887166
Sci Rep. 2015 Mar 09;5:8868
pubmed: 25746688
J Urol. 2000 Mar;163(3):806-12
pubmed: 10687982
Acta Biomater. 2021 Dec;136:456-472
pubmed: 34562660
Methods. 2020 May 1;177:2-14
pubmed: 31874237
Eur Urol. 2016 Mar;69(3):428-35
pubmed: 26166626
Nat Clin Pract Urol. 2006 Oct;3(10):526-7
pubmed: 17031375
Colloids Surf B Biointerfaces. 2019 Mar 1;175:477-486
pubmed: 30572156
J Mater Chem B. 2017 Nov 28;5(44):8821-8832
pubmed: 32264275
J Clin Oncol. 1996 Jun;14(6):1756-64
pubmed: 8656243
Chem Rev. 2012 May 9;112(5):2739-79
pubmed: 22295941
Colloids Surf B Biointerfaces. 2016 Aug 1;144:8-20
pubmed: 27058278
Nano Converg. 2019 Jul 15;6(1):23
pubmed: 31304563
CA Cancer J Clin. 2020 Nov;70(6):443-459
pubmed: 32940362
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):491-500
pubmed: 9635694
Front Pharmacol. 2018 Jul 17;9:790
pubmed: 30065653
Anal Chem. 2019 Aug 6;91(15):9348-9355
pubmed: 31264404
J Natl Cancer Inst Monogr. 2012 Dec;2012(45):146-51
pubmed: 23271765
Arch Biochem Biophys. 2016 Dec 1;611:100-112
pubmed: 27132038
Nanoscale. 2018 Dec 28;10(48):22830-22847
pubmed: 30488937
Nanomedicine. 2018 Apr 19;14(4):1407-1416
pubmed: 29680672
J Urol. 2017 Feb;197(2S):S200-S207
pubmed: 28012755
SLAS Technol. 2017 Feb;22(1):26-35
pubmed: 27659802
ACS Appl Mater Interfaces. 2016 Jun 15;8(23):14430-41
pubmed: 27219717
Sci Rep. 2022 Jan 7;12(1):55
pubmed: 34997089
Int J Radiat Oncol Biol Phys. 2021 Sep 1;111(1):220-232
pubmed: 33964351
Asian J Androl. 2018 May-Jun;20(3):221-229
pubmed: 29063869
Biosens Bioelectron. 2022 May 1;203:113979
pubmed: 35114470
Int J Nanomedicine. 2011;6:1747-56
pubmed: 21980237
Curr Opin Biotechnol. 2019 Dec;60:89-98
pubmed: 30851486
ACS Nano. 2012 Jan 24;6(1):696-704
pubmed: 22214176
J Nucl Med. 2014 Jan;55(1):107-14
pubmed: 24337602
Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18590-18596
pubmed: 31451630
Int J Nanomedicine. 2022 Mar 25;17:1409-1421
pubmed: 35369035
Cancer Res. 2004 Nov 1;64(21):7668-72
pubmed: 15520166
Acta Pharm Sin B. 2018 Jan;8(1):14-22
pubmed: 29872619
Small. 2011 Aug 8;7(15):2241-9
pubmed: 21648076
Nat Cell Biol. 2019 May;21(5):542-551
pubmed: 31048766
Anticancer Res. 2011 Dec;31(12):4445-9
pubmed: 22199313
Semin Cancer Biol. 2021 Feb;69:212-225
pubmed: 31421263
Nanomaterials (Basel). 2017 Dec 08;7(12):
pubmed: 29292780
Theranostics. 2017 Jun 25;7(10):2575-2592
pubmed: 28819448
Med Clin North Am. 2017 Jul;101(4):787-806
pubmed: 28577627
Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1424-32
pubmed: 15941951
N Engl J Med. 1991 Apr 25;324(17):1156-61
pubmed: 1707140
Chem Rev. 2013 Apr 10;113(4):2842-62
pubmed: 23509854
Biosens Bioelectron. 2022 Feb 1;197:113797
pubmed: 34818600
Bioconjug Chem. 2019 Nov 20;30(11):2727-2750
pubmed: 31593454
Acta Biomater. 2020 Aug;112:1-13
pubmed: 32470527
Biosens Bioelectron. 2017 May 15;91:293-298
pubmed: 28033558
Int J Biol Macromol. 2021 Nov 1;190:940-959
pubmed: 34478798